Skip to content
1887
Volume 45, Issue 2
  • ISSN: 0032-1400

Abstract

There is no doubt about the success of precious metals in the clinic, with, for example, platinum compounds being widely used in the treatment of cancer, silver compounds being useful antimicrobial agents and gold compounds used routinely in the treatment of rheumatoid arthritis. The medicinal properties of the other platinum group metals are now being recognised and of these a ruthenium anticancer agent has recently entered the clinic, showing promising activity on otherwise resistant tumours. Like all metal drugs, the activity of the ruthenium compounds depends on both the oxidation state and the ligands. By manipulating these features ruthenium-centred antimalarial, antibiotic and immunosuppressive drugs have been made. In addition, ruthenium has unique properties which make it particularly useful in drug design. In this review we discuss ruthenium from a clinical stance and outline the medicinal uses of ruthenium-based compounds.

Loading

Article metrics loading...

/content/journals/10.1595/003214001X4526269
2001-01-01
2024-07-23
Loading full text...

Full text loading...

/deliver/fulltext/pmr/45/2/pmr0045-0062.html?itemId=/content/journals/10.1595/003214001X4526269&mimeType=html&fmt=ahah

References

  1. Clarke M. J., Zhu F., and Frasca D. R., and , ‘Non-platinum chemotherapeutic metallopharmaceuticals’, Chem. Rep., 1999, 99, 2511-2534 [Google Scholar]
  2. Guo Z., and Sadler P. J. and , ‘Medicinal inorganic chemistry’, Adv. lnorg. Chem., 1999, 49, 183-306 [Google Scholar]
  3. Sava G., Alessio E., Bergamo A., and Mestroni G.Clarke M. J., and Sadler P. J., , and , ‘Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumor metastases’, in “Metallopharmaceuticals I, DNA Interactions”, eds. and , Springer-Verlag, Berlin, 1999, pp. 143-169 [Google Scholar]
  4. Eastman A.Lippert B., ‘The mechanism of action of cisplatin: from adducts to apoptosis’, in “Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug”, ed. , Wiley-VCH, Weinheim, 1999, pp. 111-134 [Google Scholar]
  5. Abrams M. J., and Murrer B. A. and , Science, 1993, 261, 725730 (A general reference on metals in medicine) [Google Scholar]
  6. Fricker S. P.Siegel A., and Siegel H., ‘Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs’, in “Metal Ions in Biological Systems”, Volume 36, eds. and , Marcel Dekker Inc., New York, 1999, pp. 665-721 (A review on metal compounds and nitric oxide focusing on ruthenium compounds) [Google Scholar]
  7. Abrams M. J., ‘Ruthenium Phthalocyanines’, Platinum Metals Rev., 1995, 39, (1), 14-18 [Google Scholar]
  8. Fricker S. P., ‘Ruthenium, Nitric Oxide and Disease’, Platinum Metals Rev., 1995, 39, (4), 150-159 [Google Scholar]
/content/journals/10.1595/003214001X4526269
Loading
/content/journals/10.1595/003214001X4526269
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error